Drug exposure,pregnancy outcome and fetal and childhood development occurring in the offspring of mothers with systemic lupus erythematosus and other chronic autoimmune diseases
Restricted accessResearch articleFirst published online November, 2006
Drug exposure,pregnancy outcome and fetal and childhood development occurring in the offspring of mothers with systemic lupus erythematosus and other chronic autoimmune diseases
Most autoimmune diseases occur more commonly in females and many of these young women wish to become mothers. For pregnancy to proceed successfully immunomodulation and physiological changes preparing the reproductive system need to occur. Pregnancy occurring in a chronically ill mother who requires medications in order to maintain her own health and who may have already incurred significant organ pathology gives rise to several problems and so four questions arise: 1) What will be the effect of the pregnancy on the underlying disease? 2) What will be the effect of the disease on the outcome of pregnancy? 3) How to manage the disease, just prior to, throughout and immediately after the pregnancy? 4) The long term fetal and childhood effects of maternal disease and its management. This paper reviews the current literature pertaining to these questions in patients with systemic lupus erythematosus (SLE) and other chronic rheumatic and autoimmune diseases.
Hench PS . The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis, and intermittent hydrarthrosis . Mayo Clin Proc1938; 13: 161–167 .
2.
Poser S , Poser N , Multiple sclerosis and gestation . Neurology1983; 33: 1422–1427 .
3.
Petri M . Hopkins Lupus Pregnancy Center 1987–1996 . Rheum Disease Clinics of North America1997; 23: 1–13 .
4.
Ramsey-Goldman R , Kutzer JE , Kuller LH et al. Previous pregnancy outcome is an important determinant of subsequent pregnancy outcome in women with systemic lupus erythematosus . Am J Reprod Immunol1992; 28: 195–198 .
5.
Lockshin MD . Pathogenesis of the antiphospholipid antibody syndrome . Lupus1996; 5: 404–408 .
6.
Traverse W , Tendler B , Galea C et al. Neuroendocrine manifestations of phospholipid antibody disease identified by long-term follow-up study of patients with phospholipid antibodies . Annals NYAS2006; 1069(1): 386–390 .
7.
Piccinni MP , Maggie M , Romagnani S . Role of hormone controlled T cell cytokines in the maintenance of pregnancy . Biochem Soc Trans2000; 28: 212–215 .
8.
Chaouat G , Assa I , Malien IA et al. IL-10 prevents naturally occurring fetal loss in the CBA x DBA/2 mating combination and local defect in IL-10 production in the abortion prone combination is corrected by in vivo injection of IFN-TAU . J Immuno1995; 154: 4261–4268 .
9.
Dhar PJ , Essenmacher LM , Ager JW et al. Pregnancy outcomes before and after a diagnosis of systemic lupus erythematosus . AMJ Obsete Gynecol2005; 193(4): 444–455 .
10.
Chakravarty EF , Colon I , Langen BA et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus . AMJ Obstet and Gynecol2005; 192(6): 1897–1904 .
11.
Miyakis S . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS .) J Thromb Haemost2006; 4: 295–306 .
12.
Out HJ , Kooijman CP , Bruinse HW et al. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospho-lipid antibodies . Eur J Obstet Gyn Reprod Biol1999; 41: 179–186 .
13.
Parke AL . Placental pathology in antiphospholipid antibody syndrome. In khamashta MA ed. Hughes Syndrome. Springer, 2006: 326–374.
14.
Lubbe WF , Palmer SJ , Butler WS et al. Fetal survival after prednisone suppression of maternal lupus anticoagulant . Lancet1983; 1: 1361–1363 .
15.
Tincani A , Branch W , Levy RA et al. Treatment of pregnant patients with antiphospholipid syndrome . Lupus2003; 12: 524–529 .
16.
Lakasing L . Obstetric complication due to autoantibodies . Best Practice & Research Clin Endocrino & Metabolism2005; 19: 149–175 .
17.
Pop VJ , Brouwers EP , Vader HL et al. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study . Clin Endocrinol (Oxf)2003; 59: 282-282 .
18.
Fisher DA . Fetal thyroid function: Diagnosis and management of fetal thyroid disorder . Clin Obstet Gyncol1997; 40: 16–31 .
19.
Reed BR , Lee LA , Harmon C et al. Autoantibodies to SS-A/Ro in infants with congenital heart block . J Pediatr1983; 103: 889–891 .
Brucato A , Frass IM , Franceschin F et al. Risk of congenital complete heart block in newborns of mother with anti Ro/SSA antibodies detected by counter immuno electrophoresis: A prospective study of 100 women . Arthritis & Rheum2001; 44: 1832–1835 .
22.
Solomon DG , Rupel A , Buyon JP . Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling . Lupus2003; 12: 646–647 .
23.
Saleeb S , Copel J , Friedman D et al. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody associated congenital heart block: Retrospective review of the Research Registry for Neonatal Lupus . Arthritis and Rheum1999; 4: 2335–2345 .
24.
Buyon JP , Hiebert R , Copel J et al. Autoimmune-associated congenital heart block: Mortality, morbidity, and recurrence rates, obtained from a national neonatal lupus registry . J Am Coll Cardiol1998; 31: 1658–1666 .
25.
Neild LE , Silverman ED , Taylor GP et al. Maternal anti Ro and anti La anti-body associated endocardial fibroelastosis . Circulation2002; 9: 842–848 .
26.
Askanase AD , Friedman DM , Dischem MR et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti SSA/Ro/SSB La antibodies . Lupus2002; 11: 145–151 .
27.
Jaeggi ET , Hamilton RM , Silverman ED et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years . J Am Coll Cardiol2002; 39: 130–137 .
28.
Boffa MC , Aurousseau MH , Lachassinne E et al. European register of babies born to mother with antiphospholipid syndrom . Lupus2004; 13: 713–717 .
29.
Lojacono A , Spatola L , Faden D et al. Foetal stroke associated with maternal antiphospholipid antibodies: a case report . Lupus1996; 5: 512-512 .
30.
Zurgil N , Bakimer R , Tincani A et al. Detection of anti-phospholipid and anti-DNA antibodies and their idiotypes in newborns of mothers with anti-phospholipid syndrome and SLE . Lupus1993; 2: 233–237 .
31.
Ostensen M , Khamashta M , Lockshin M et al. Anti-inflammatory and immunosuppressive drugs and repordution . Arthritis Research & Therapy2006; 8: 209-209 .
32.
Ross G , Sammaritano L , Nass R et al. Effects of mother's autoimmune disease during pregnancy on learning disabilities and hand preference in their children . Arch Ped Med2003; 57: 397–402 .
33.
Garite TJ , Clark R , Thorp JA . Intrauterine growth restriction increases morbidity and mortality among premature neonatesAmer J Obstetyrics and Gynecol2004; 191(2): 481–487 .
34.
Msall ME , Tremont MR . Functional out-comes in self-care, mobility, communication, and learning in extremely low-birth weight infants . Clin Perinatol2000; 27: 381–401 .
35.
Robinson R . The fetal origins of adult disease . Br Med J2001; 322(7283): 375–376 .
36.
Branch DW , Scott JR , Kochenour NK et al. Obstetric complications associated with lupus anticoagulant . NEJM1985; 313: 1322–1326 .
37.
Herbst AL , Ulfelder H , Poskanzer DC . Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women . MEJM1971; 284: 878–881 .
38.
Kaufman RH , Adam E , Hatch EE et al. Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring . Obstet Gynecol2000; 96: 483–489 .
39.
Cosgrove MD , Benton B , Henderson BE . Male genitourinary abnormalities and maternal diethylstilbestrolJ Urol1977; 177: 220–222 .
40.
Noller KL , Blair PB , Obrien PC et al. Increased occurrence of autoimmune disease among women exposed in utero to diethylstilbestrol . Fertil Steril1988; 49: 1080–1087 .
41.
McKay DB , Josephson M . Pregnancy in recipients of solid organs–effects on mother and child . NEJM2006; 354: 1281–1293 .
42.
Armenti VT , Radomski JS , Mortiz MJ et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation In Cecka JM , Terasaki PI eds. Clinical transplants. UCLA Immunogenetics Center , 2004: 103–119.
43.
Sibanda N , Briggs JD , Davison JM et al. Outcomes of pregnancy after renal transplantation: a report of UK Transplant Pregnancy Registry . Hypertens Pregnancy2004; 23(Suppl): 136-136 .
44.
EBPG Expert Group in Renal . European best practice guidelines for renal transplantation. Section IV.10. Long-term management of the transplant recipient–pregnancy in renal transplant recipients . Nephrol Dial Transplant2002; 17(Suppl 4): 50–58
45.
Stratta P , Canavese C , Giacchino F et al. Pregnancy in kidney transplantation: satisfactory outcome and harsh realities . J Nephrol2003; 16: 792–806 .
46.
Scott JR , Branch DW , Holman J . Autoimmune and pregnancy complications in the daughter of a kidney transplant patient . Transplantation2002; 73: 815–816 .
47.
Stanley CW , Gottlieb R , Zager R et al. Developmental well-being in offspring of women receiving cyclosporine post-renal transplant . Transplant Proc1999; 31: 241–242 .
48.
Cimaz R , Meregalli E , Biggioggero M . Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy . Toxicology Letters2004; 149: 155–162 .
49.
Rudnicki RD , Gresham GE , Rothfield NF . The efficacy of anti malarials in SLE . J Rheum1975; 2: 323–330 .
50.
The Canadian Hudroxychloroquine Study Group . A ramdomized study of the effect of withdrawing hydroxychloroquine sulfate in SLE . New Eng J Med1991; 324: 150–154 .
51.
Ullberg S , Lindquist NJ , Sjostrand SE . Accumulation of chorioretinotoxic drugs in the fetal eye . Nature1970; 227: 1257–1258 .
52.
Motta M , Tincani A , Faden D . Follow-up of infants exposed to hydroxychloroquine. given to mothers during pregnancy and lactation . J Perinatol. 2005; 25; 86–89 .
53.
Borba EF , Turrini-Filho JR , Kuruma KAM . Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry . Lupus2004; 13: 223–227 .
54.
Cimaz R , Brucato A , Meregalli E et al. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: Comment on the article by Costedoat-Chalumeau et al . Arthritis & Rheum2004; 50: 3056–3057 .
55.
Baud O , Foiz-L'Helias L , Kaminski M et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants . NEJM1999; 341: 1190–1196 .
56.
Spinillo A , Viazzo F , Colleoni R et al. Two year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity . Amer J Obstet and Gynecol2004; July 1: 191-191 .
